nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—Subarachnoid haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0497	0.0535	CcSEcCtD
Bosentan—Panophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0444	0.0479	CcSEcCtD
Bosentan—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.0291	0.0314	CcSEcCtD
Bosentan—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.0291	0.0314	CcSEcCtD
Bosentan—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0228	0.0246	CcSEcCtD
Bosentan—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.0178	0.0192	CcSEcCtD
Bosentan—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.0159	0.0171	CcSEcCtD
Bosentan—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.0158	0.017	CcSEcCtD
Bosentan—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.0146	0.0158	CcSEcCtD
Bosentan—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0155	CcSEcCtD
Bosentan—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.0144	0.0155	CcSEcCtD
Bosentan—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.0139	0.015	CcSEcCtD
Bosentan—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0139	CcSEcCtD
Bosentan—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.012	0.0129	CcSEcCtD
Bosentan—Gout—Riluzole—amyotrophic lateral sclerosis	0.0116	0.0125	CcSEcCtD
Bosentan—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0124	CcSEcCtD
Bosentan—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.011	0.0119	CcSEcCtD
Bosentan—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0117	CcSEcCtD
Bosentan—EDNRB—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.0105	0.144	CbGpPWpGaD
Bosentan—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0111	CcSEcCtD
Bosentan—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0102	0.011	CcSEcCtD
Bosentan—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0098	0.0106	CcSEcCtD
Bosentan—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00965	0.0104	CcSEcCtD
Bosentan—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00905	0.00976	CcSEcCtD
Bosentan—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.009	0.00971	CcSEcCtD
Bosentan—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00876	0.00944	CcSEcCtD
Bosentan—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0083	0.00895	CcSEcCtD
Bosentan—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00827	0.00892	CcSEcCtD
Bosentan—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00806	0.0087	CcSEcCtD
Bosentan—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.0079	0.00852	CcSEcCtD
Bosentan—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00781	0.00842	CcSEcCtD
Bosentan—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00775	0.00835	CcSEcCtD
Bosentan—EDNRA—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.0075	0.103	CbGpPWpGaD
Bosentan—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00748	0.00807	CcSEcCtD
Bosentan—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00745	0.00804	CcSEcCtD
Bosentan—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00732	0.00789	CcSEcCtD
Bosentan—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00727	0.00783	CcSEcCtD
Bosentan—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00719	0.00775	CcSEcCtD
Bosentan—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00716	0.00772	CcSEcCtD
Bosentan—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00685	0.00738	CcSEcCtD
Bosentan—Influenza—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00733	CcSEcCtD
Bosentan—Asthma—Riluzole—amyotrophic lateral sclerosis	0.0068	0.00733	CcSEcCtD
Bosentan—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00663	0.00714	CcSEcCtD
Bosentan—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00654	0.00705	CcSEcCtD
Bosentan—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00686	CcSEcCtD
Bosentan—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00686	CcSEcCtD
Bosentan—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00628	0.00678	CcSEcCtD
Bosentan—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00619	0.00667	CcSEcCtD
Bosentan—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00615	0.00664	CcSEcCtD
Bosentan—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00658	CcSEcCtD
Bosentan—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00606	0.00654	CcSEcCtD
Bosentan—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00606	0.00654	CcSEcCtD
Bosentan—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00598	0.00645	CcSEcCtD
Bosentan—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00641	CcSEcCtD
Bosentan—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00591	0.00637	CcSEcCtD
Bosentan—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00591	0.00637	CcSEcCtD
Bosentan—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00589	0.00636	CcSEcCtD
Bosentan—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00578	0.00624	CcSEcCtD
Bosentan—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00574	0.00618	CcSEcCtD
Bosentan—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00572	0.00617	CcSEcCtD
Bosentan—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00569	0.00614	CcSEcCtD
Bosentan—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00554	0.00598	CcSEcCtD
Bosentan—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00547	0.0059	CcSEcCtD
Bosentan—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00587	CcSEcCtD
Bosentan—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00544	0.00587	CcSEcCtD
Bosentan—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00542	0.00584	CcSEcCtD
Bosentan—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00538	0.0058	CcSEcCtD
Bosentan—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00536	0.00578	CcSEcCtD
Bosentan—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00534	0.00575	CcSEcCtD
Bosentan—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00515	0.00555	CcSEcCtD
Bosentan—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00509	0.00549	CcSEcCtD
Bosentan—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00505	0.00545	CcSEcCtD
Bosentan—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00494	0.00533	CcSEcCtD
Bosentan—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00492	0.0053	CcSEcCtD
Bosentan—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00491	0.00529	CcSEcCtD
Bosentan—Chills—Riluzole—amyotrophic lateral sclerosis	0.00488	0.00527	CcSEcCtD
Bosentan—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00477	0.00514	CcSEcCtD
Bosentan—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00474	0.00511	CcSEcCtD
Bosentan—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00467	0.00504	CcSEcCtD
Bosentan—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00494	CcSEcCtD
Bosentan—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00456	0.00491	CcSEcCtD
Bosentan—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00444	0.00479	CcSEcCtD
Bosentan—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00438	0.00472	CcSEcCtD
Bosentan—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00433	0.00467	CcSEcCtD
Bosentan—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00459	CcSEcCtD
Bosentan—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00425	0.00458	CcSEcCtD
Bosentan—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00424	0.00457	CcSEcCtD
Bosentan—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00419	0.00452	CcSEcCtD
Bosentan—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00417	0.00449	CcSEcCtD
Bosentan—Cough—Riluzole—amyotrophic lateral sclerosis	0.00414	0.00446	CcSEcCtD
Bosentan—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00435	CcSEcCtD
Bosentan—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00403	0.00435	CcSEcCtD
Bosentan—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00434	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00432	CcSEcCtD
Bosentan—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00399	0.0043	CcSEcCtD
Bosentan—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00395	0.00425	CcSEcCtD
Bosentan—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00417	CcSEcCtD
Bosentan—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00417	CcSEcCtD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00385	0.053	CbGpPWpGaD
Bosentan—Infection—Riluzole—amyotrophic lateral sclerosis	0.00384	0.00414	CcSEcCtD
Bosentan—Shock—Riluzole—amyotrophic lateral sclerosis	0.00381	0.0041	CcSEcCtD
Bosentan—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00409	CcSEcCtD
Bosentan—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00408	CcSEcCtD
Bosentan—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00377	0.00407	CcSEcCtD
Bosentan—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00405	CcSEcCtD
Bosentan—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00374	0.00403	CcSEcCtD
Bosentan—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00369	0.00398	CcSEcCtD
Bosentan—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00361	0.0039	CcSEcCtD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.0036	0.0496	CbGpPWpGaD
Bosentan—EDNRB—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00354	0.0487	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00352	0.0038	CcSEcCtD
Bosentan—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.0035	0.00377	CcSEcCtD
Bosentan—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00375	CcSEcCtD
Bosentan—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00345	0.00372	CcSEcCtD
Bosentan—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00344	0.00371	CcSEcCtD
Bosentan—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.0034	0.00367	CcSEcCtD
Bosentan—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00363	CcSEcCtD
Bosentan—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00334	0.0036	CcSEcCtD
Bosentan—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0036	CcSEcCtD
Bosentan—Pain—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00357	CcSEcCtD
Bosentan—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00357	CcSEcCtD
Bosentan—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00341	CcSEcCtD
Bosentan—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00331	CcSEcCtD
Bosentan—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00306	0.0033	CcSEcCtD
Bosentan—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00306	0.0033	CcSEcCtD
Bosentan—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00307	CcSEcCtD
Bosentan—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00277	0.00299	CcSEcCtD
Bosentan—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00274	0.00295	CcSEcCtD
Bosentan—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00265	0.00285	CcSEcCtD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00258	0.0355	CbGpPWpGaD
Bosentan—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00276	CcSEcCtD
Bosentan—EDNRA—Peptide GPCRs—C5AR1—amyotrophic lateral sclerosis	0.00253	0.0349	CbGpPWpGaD
Bosentan—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00265	CcSEcCtD
Bosentan—Rash—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00263	CcSEcCtD
Bosentan—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00263	CcSEcCtD
Bosentan—Headache—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00261	CcSEcCtD
Bosentan—Nausea—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00248	CcSEcCtD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00203	0.0279	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—PLA2G4A—amyotrophic lateral sclerosis	0.00199	0.0274	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.00193	0.0266	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.00167	0.0229	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00145	0.02	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—PLA2G4A—amyotrophic lateral sclerosis	0.00142	0.0196	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00128	0.0177	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.00119	0.0164	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00112	0.0154	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000851	0.0117	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000847	0.0117	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000799	0.011	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000769	0.0106	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000727	0.01	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000703	0.00968	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000654	0.009	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000615	0.00846	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000609	0.00838	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.00052	0.00716	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000488	0.00671	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000481	0.00662	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000437	0.00601	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000421	0.0058	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000371	0.00511	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000368	0.00507	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000349	0.0048	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000344	0.00474	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000343	0.00471	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000343	0.00471	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00034	0.00468	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000333	0.00459	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.00032	0.0044	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000319	0.0044	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000313	0.00431	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000312	0.0043	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000303	0.00417	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000294	0.00404	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000291	0.00401	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000274	0.00377	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000266	0.00366	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000261	0.00359	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000258	0.00355	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000257	0.00353	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—DAO—amyotrophic lateral sclerosis	0.000248	0.00341	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000244	0.00335	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000235	0.00323	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000229	0.00315	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00022	0.00303	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000218	0.00301	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000217	0.00299	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000216	0.00297	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00021	0.00289	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.00021	0.00289	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000208	0.00286	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000205	0.00283	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000191	0.00262	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000188	0.00258	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000187	0.00257	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000185	0.00254	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000177	0.00244	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSR—amyotrophic lateral sclerosis	0.000173	0.00238	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000166	0.00229	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000158	0.00218	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	0.000158	0.00217	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000154	0.00212	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.00015	0.00207	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000149	0.00205	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000147	0.00203	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000142	0.00196	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000141	0.00194	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000136	0.00188	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000135	0.00186	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	0.00013	0.00179	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000127	0.00175	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000127	0.00175	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000119	0.00164	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000114	0.00157	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000114	0.00157	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000113	0.00156	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000113	0.00155	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000107	0.00147	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000105	0.00144	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000105	0.00144	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.84e-05	0.00135	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.72e-05	0.00134	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.71e-05	0.00134	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	9.69e-05	0.00133	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	9.14e-05	0.00126	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.11e-05	0.00125	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	8.89e-05	0.00122	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.66e-05	0.00119	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	8.27e-05	0.00114	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.06e-05	0.00111	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.64e-05	0.00105	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	7.54e-05	0.00104	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	7.54e-05	0.00104	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.5e-05	0.00103	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.02e-05	0.000967	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	6.9e-05	0.000949	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.66e-05	0.000917	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.41e-05	0.000883	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.3e-05	0.000867	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	6.27e-05	0.000862	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.2e-05	0.000853	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	6.03e-05	0.00083	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	5.78e-05	0.000796	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—APOE—amyotrophic lateral sclerosis	5.78e-05	0.000796	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.66e-05	0.000778	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	5.45e-05	0.000751	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.27e-05	0.000725	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.77e-05	0.000657	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	4.75e-05	0.000654	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.51e-05	0.00062	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.33e-05	0.000596	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.27e-05	0.000588	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.13e-05	0.000569	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.05e-05	0.000557	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.96e-05	0.000545	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.81e-05	0.000525	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.13e-05	0.000431	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.06e-05	0.000421	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.97e-05	0.000409	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.55e-05	0.000351	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.35e-05	0.000323	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.93e-05	0.000266	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.68e-05	0.000232	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.55e-05	0.000213	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.32e-05	0.000182	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.27e-05	0.000175	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.72e-06	0.00012	CbGpPWpGaD
